FEIBA on-demand therapy is proven effective

FEIBA is an integral part of treatment strategy, helping to manage bleeding episodes, minimize joint damage, and preserve patients mobility.2,3

  • Up to 93% effi cacy in bleeding episodes (153/165) in a prospective study2
  • 79% (83/106) of bleeding episodes were controlled within 36 hours of the first infusion4

References

  1. 1. Astermark J, Donfi eld SM, DiMichele DM, et al; for the FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109:546-551.
  2. 2. Hilgartner MW, Knatterud GL, and the FEIBA Study Group. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood. 1983;61:36-40.
  3. 3. US National Hemophilia Foundation. MASAC Recommendation 167 Regarding the Use of Bypassing Agents in Patients with Hemophilia A or B and Inhibitors. Available at: http://www.hemophilia.org/ NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=579. Accessed July 2011.
  4. 4. Hilgartner M, Aledort L. Andes A, Gill J, and the members of the FEIBA Study Group. Effi cacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion. 1990;30:626-630.
  5. 5. DiMichele D, Négrier C. A retrospective postlicensure survey of FEIBA effi cacy and safety. Haemophilia. 2006;12:352-362.
  6. 6. Négrier C, and the French FEIBA Study Group. FEIBA VH in home treatment: a 3-year prospective experience [abstract]. Haemophilia. 1998;4:238. Abstract 330.
  7. 7. Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost. 1997;77:1113-1119.
  8. 8. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007;13:249-255.

Rapid onset and sustained activity

FEIBA stops bleeds quickly and offers a long dosing interval. Read more

Integral to inhibitor management

Learn how FEIBA is integral to the management of patients with inhibitors. Read more

On Demand

Learn the use of FEIBA in on-demand therapy. Read more